Clinical trial
BAY12-8039: 5 Days for Sinusitis vs Placebo
NCT00492024 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00492024 |
|---|---|
| Title | BAY12-8039: 5 Days for Sinusitis vs Placebo |
| Official title | Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg QD for 5 Days Versus Placebo in the Treatment of Acute Bacterial Sinusitis |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sinusitis |
| Intervention type | Drug |
| Interventions | Moxifloxacin (Avelox, BAY12-8039), Placebo |
| Enrollment | 374 |
| Start date | Jan 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jun 27, 2007 |
| Last update posted | Nov 26, 2013 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: